A PHASE II STUDY OF STRIDE (DURVALUMAB + TREMELIMUMAB) WITH LENVATINIB
VERSUS STRIDE ALONE IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
(STRIDE-HCC)
- Registry ID
- HE.2
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY
- Start date
- 2025-05-30
- Last update
- 2025-04-30
Conditions
- UNRESECTABLE HEPATOCELLULAR CARCINOMA
View on source registry